ME02417B - Kondenzovani derivati imidazola koji su korisni kao ido inhibitori - Google Patents

Kondenzovani derivati imidazola koji su korisni kao ido inhibitori

Info

Publication number
ME02417B
ME02417B MEP-2016-82A MEP201682A ME02417B ME 02417 B ME02417 B ME 02417B ME P201682 A MEP201682 A ME P201682A ME 02417 B ME02417 B ME 02417B
Authority
ME
Montenegro
Prior art keywords
imidazole derivatives
derivatives useful
ido inhibitors
fused imidazole
fused
Prior art date
Application number
MEP-2016-82A
Other languages
German (de)
English (en)
French (fr)
Inventor
Mario Mautino
Sanjeev Kumar
Jesse Waldo
Firoz Jaipuri
Tanay Kesharwani
Xiaoxia Zhang
Original Assignee
Newlink Genetics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newlink Genetics Corp filed Critical Newlink Genetics Corp
Publication of ME02417B publication Critical patent/ME02417B/me

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MEP-2016-82A 2011-04-15 2012-04-12 Kondenzovani derivati imidazola koji su korisni kao ido inhibitori ME02417B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161475788P 2011-04-15 2011-04-15
PCT/US2012/033245 WO2012142237A1 (en) 2011-04-15 2012-04-12 Fused imidazole derivatives useful as ido inhibitors
EP12715295.7A EP2697227B1 (en) 2011-04-15 2012-04-12 Fused imidazole derivatives useful as ido inhibitors

Publications (1)

Publication Number Publication Date
ME02417B true ME02417B (me) 2016-09-20

Family

ID=45976556

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2016-82A ME02417B (me) 2011-04-15 2012-04-12 Kondenzovani derivati imidazola koji su korisni kao ido inhibitori

Country Status (30)

Country Link
US (5) US9260434B2 (me)
EP (3) EP3348558A1 (me)
JP (4) JP2014511876A (me)
KR (1) KR102164443B1 (me)
CN (2) CN103547579B (me)
AU (4) AU2012242871C1 (me)
BR (1) BR112013026494A2 (me)
CA (1) CA2833296C (me)
CL (1) CL2013002990A1 (me)
CO (1) CO6862146A2 (me)
CY (1) CY1117440T1 (me)
DK (2) DK2697227T3 (me)
ES (2) ES2660831T3 (me)
HK (1) HK1256355A1 (me)
HR (2) HRP20160369T1 (me)
HU (2) HUE038586T2 (me)
IL (3) IL228862A (me)
LT (1) LT3018132T (me)
ME (1) ME02417B (me)
MX (1) MX340442B (me)
NO (1) NO2694640T3 (me)
NZ (2) NZ708090A (me)
PE (2) PE20141124A1 (me)
PL (2) PL3018132T3 (me)
PT (1) PT3018132T (me)
RS (2) RS54723B1 (me)
RU (2) RU2613579C2 (me)
SI (2) SI3018132T1 (me)
SM (1) SMT201600130B (me)
WO (1) WO2012142237A1 (me)

Families Citing this family (296)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2694640T3 (me) * 2011-04-15 2018-03-17
WO2013009701A2 (en) 2011-07-08 2013-01-17 The University Of North Carolina At Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
SG11201507255QA (en) 2013-03-14 2015-10-29 Newlink Genetics Corp Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
CN105209449B (zh) 2013-03-14 2019-02-01 ćș“æ‹‰ćŸ·ć€«ćˆ¶èŻç§äșșæœ‰é™ć…Źćž çŠŹć°żæ°šé…žé€”ćŸ„çš„æŠ‘ćˆ¶ć‰‚
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
CN103382187B (zh) * 2013-08-06 2015-06-03 äżĄćźžç”Ÿç‰©ćŒ»èŻïŒˆäžŠæ”·ïŒ‰æœ‰é™ć…Źćž 侀种3-æ°Ż-7(5)-æșŽè‹Żćč¶ćŒ‚æ¶ć”‘çš„ćˆæˆæ–čæł•
ES2857848T3 (es) 2013-12-24 2021-09-29 Bristol Myers Squibb Co Compuestos tricĂ­clicos como agentes antineoplĂĄsicos
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
PT3151921T (pt) 2014-06-06 2019-11-21 Bristol Myers Squibb Co Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizaçÔes dos mesmos
SG10201804868PA (en) * 2014-09-05 2018-07-30 Merck Patent Gmbh Compounds for the inhibition of indoleamine-2,3-dioxygenase
GB201417369D0 (en) * 2014-10-01 2014-11-12 Redx Pharma Ltd Compounds
GB201418300D0 (en) * 2014-10-15 2014-11-26 Redx Pharma Ltd Compounds
JP6882978B2 (ja) 2014-10-29 2021-06-02 ăƒă‚€ă‚čă‚Żăƒ«ă‚ąăƒŒăƒ«ăƒ‡ă‚ŁăƒŒăƒ»ăƒȘミテッド ïŒ­ïœ”ïŒ‘âˆ’ïœïœïœă«ç‰č異的ăȘäșŒç’°æ€§ăƒšăƒ—ăƒăƒ‰ăƒȘガンド
MY189836A (en) 2014-11-21 2022-03-11 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
US10525035B2 (en) 2014-12-18 2020-01-07 Lankenau Institute For Medical Research Methods and compositions for the treatment of retinopathy and other ocular diseases
TW201630907A (zh) 2014-12-22 2016-09-01 濅æČ»ćŠ„çŸŽé›…ćČè°·æŻ”ć…Źćž ÎČïŒČæ‹źæŠ—ćŠ‘
CN107207594B (zh) 2014-12-23 2019-05-07 ç™Ÿæ—¶çŸŽæ–œèŽ”ćźć…Źćž 针ćŻčtigit的抗䜓
US10983128B2 (en) 2015-02-05 2021-04-20 Bristol-Myers Squibb Company CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
CN105884828A (zh) * 2015-02-16 2016-08-24 䞊攷èżȘèŻșćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž ć€šçŽŻćŒ–ćˆç‰©ă€ć…¶èŻç‰©ç»„ćˆç‰©ćŠćș”甚
ES2789331T3 (es) 2015-03-02 2020-10-26 Rigel Pharmaceuticals Inc Inhibidores de TGF-beta
KR20170134980A (ko) 2015-04-03 2017-12-07 ëžŒëŠŹìŠ€í†š-마읎얎슀 슀큅 컎퍌니 암의 ìč˜ëŁŒë„Œ 위한 ìžëŒì•„ëŻŒ-2,3-디옄시êČŒë‚˜ì œì˜ 얔제제
TW201642897A (zh) 2015-04-08 2016-12-16  æ˜Ÿç”Ÿç‰©ç§‘æŠ€æœ‰é™ć…Źćž ïŒšïœ…ïœ’ïŒ’ç”ćˆćŠ‘æČ»ç™‚
JP6806342B2 (ja) * 2015-04-10 2021-01-06 ăƒ™ă‚€ă‚žăƒŒăƒł ăƒȘミテッド ă‚€ăƒłăƒ‰ăƒŒăƒ«ă‚ąăƒŸăƒłăšă—ăŠăźæ–°èŠïŒ•ćˆăŻïŒ˜âˆ’çœźæ›ă‚€ăƒŸăƒ€ă‚ŸïŒ»ïŒ‘ïŒŒïŒ•âˆ’ïœïŒœăƒ”ăƒȘă‚žăƒłéĄžă€ćŠăłïŒćˆăŻăƒˆăƒȘăƒ—ăƒˆăƒ•ă‚ĄăƒłïŒ’ïŒŒïŒ“âˆ’ă‚žă‚Șă‚­ă‚·ă‚ČăƒŠăƒŒă‚Œ
JP2018511647A (ja) 2015-04-12 2018-04-26 ハンゾョォ ă‚€ăƒŽă‚ČăƒŒăƒˆ ăƒ•ă‚ĄăƒŒăƒž ă‚«ăƒłăƒ‘ăƒ‹ăƒŒ ăƒȘăƒŸăƒ†ăƒƒăƒ‰ïŒšïœïœŽïœ‡ïœšïœˆïœïœ•   ïŒŁïœïŒŽïŒŒïŒŹïœ”ïœ„ïŒŽ ïŒ©ïœ„ïœé˜»ćźłć‰€ăšïœ”ïœ„ïœé˜»ćźłć‰€ăšă—ăŠăźè€‡çŽ ç’°ćŒ–ćˆç‰©
BR112017020952A2 (pt) 2015-04-13 2018-07-10 Five Prime Therapeutics Inc método de tratamento de cùncer, composição e uso da composição
JP6801159B2 (ja) * 2015-04-21 2020-12-16 ゾスンă‚č ăƒ˜ăƒłăƒ«ă‚€ ăƒĄăƒ‡ă‚€ă‚·ăƒłă‚«ăƒłăƒ‘ăƒ‹ăƒŒ ăƒȘミテッドïŒȘ   ïŒŁïœïŒŽïŒŒïŒŹïœ”ïœ„ïŒŽ ă‚€ăƒŸăƒ€ă‚Ÿă‚€ă‚œă‚€ăƒłăƒ‰ăƒŒăƒ«èȘ˜ć°Žäœ“ă€ăăźèŁœé€ æ–čæł•ćŠăłăăźćŒ»è–Źç”šé€”
EP3294736B1 (en) 2015-05-11 2020-07-22 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
EP3307740B1 (en) 2015-05-12 2019-12-18 Bristol-Myers Squibb Company 5h-pyrido[3,2-b]indole compounds as anticancer agents
US9725449B2 (en) 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
TN2019000101A1 (en) 2015-05-29 2020-07-15 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof.
GB2548542A (en) * 2015-06-16 2017-09-27 Redx Pharma Plc Compounds
CN106256830B (zh) * 2015-06-18 2019-03-08 æˆéƒœæ”·ćˆ›èŻäžšæœ‰é™ć…Źćž äž€ç§æ°˜ä»Łçš„idoæŠ‘ćˆ¶ć‰‚ćŠć…¶ćˆ¶ć€‡æ–čæł•ć’Œç”šé€”
AU2016285920A1 (en) 2015-06-29 2018-02-01 Bristol-Myers Squibb Company Antibodies to CD40 with enhanced agonist activity
CN105037371A (zh) * 2015-06-30 2015-11-11 è„żćŽć€§ć­Š äž€ç§æ°˜ä»Łçš„ćČ據èƒș-2,3-ćŒćŠ æ°§é…¶æŠ‘ćˆ¶ć‰‚
GB201511790D0 (en) 2015-07-06 2015-08-19 Iomet Pharma Ltd Pharmaceutical compound
IL274572B2 (en) 2015-07-16 2024-01-01 Biolinerx Ltd Compositions and methods for treating cancer
EP3954369B1 (en) 2015-07-24 2025-08-20 Lumos Pharma, Inc. Salts and prodrugs of 1-methyl-d-tryptophan
CN108137597A (zh) 2015-07-28 2018-06-08 ç™Ÿæ—¶çŸŽæ–œèŽ”ćźć…Źćž TGFÎČć—äœ“æ‹źæŠ—ć‰‚
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
WO2017035118A1 (en) 2015-08-25 2017-03-02 Bristol-Myers Squibb Company Tgf beta receptor antagonists
CN106478634B (zh) * 2015-09-01 2020-05-22 ć°šćŽćŒ»èŻç§‘æŠ€(æ±Ÿè„ż)æœ‰é™ć…Źćž 皠搈ć’Șć”‘ćŒ–ćˆç‰©ă€ć…¶ćˆ¶ć€‡æ–čæł•ă€èŻç‰©ç»„ćˆç‰©ć’Œç”šé€”
WO2017075341A1 (en) * 2015-10-29 2017-05-04 Scifluor Life Sciences, Inc. Fused imidazole derivatives as ido/tdo inhibitors
AU2016350701B2 (en) 2015-11-02 2021-08-19 Five Prime Therapeutics, Inc. CD80 extracellular domain polypeptides and their use in cancer treatment
WO2017080934A1 (en) * 2015-11-09 2017-05-18 F. Hoffmann-La Roche Ag Screening assay to identify id01 and/or tdo modulators
BR112018010172A2 (pt) 2015-11-19 2018-11-21 Bristol Myers Squibb Co anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
US20170145103A1 (en) 2015-11-23 2017-05-25 Five Prime Therapeutics, Inc. Predicting response to cancer treatment with fgfr2 inhibitors
KR102738306B1 (ko) 2015-12-15 2024-12-03 ëžŒëŠŹìŠ€í†š-마읎얎슀 슀큅 컎퍌니 Cxcr4 수용ìČŽ êžží•­ì œ
TW201730190A (zh) * 2015-12-24 2017-09-01 Genentech Inc ïŒŽïœ„ïœïŒ’æŠ‘ćˆ¶ćŠ‘
CN107056785B (zh) * 2016-01-02 2021-06-22 æ­ć·žè‹±ćˆ›ćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž 䜜äžșido撌tdoæŠ‘ćˆ¶ć‰‚çš„æ‚çŽŻćŒ–ćˆç‰©
AU2017215424A1 (en) * 2016-02-02 2018-08-09 Emcure Pharmaceuticals Limited Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
CN108884104B (zh) * 2016-02-19 2021-01-15 æ­Łć€§ć€©æ™ŽèŻäžšé›†ć›ąè‚Ąä»œæœ‰é™ć…Źćž 䜜äžșć…ç–«è°ƒèŠ‚ć‰‚çš„äž‰ćč¶çŽŻćŒ–ćˆç‰©
US11752131B2 (en) 2016-02-19 2023-09-12 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of obesity
CN112898309A (zh) * 2016-02-19 2021-06-04 æ­Łć€§ć€©æ™ŽèŻäžšé›†ć›ąè‚Ąä»œæœ‰é™ć…Źćž 䜜äžșć…ç–«è°ƒèŠ‚ć‰‚çš„äž‰ćč¶çŽŻćŒ–ćˆç‰©
WO2017149469A1 (en) 2016-03-03 2017-09-08 Emcure Pharmaceuticals Limited Heterocyclic compounds useful as ido and/or tdo modulators
KR20230038311A (ko) 2016-03-04 2023-03-17 ëžŒëŠŹìŠ€í†š-마읎얎슀 슀큅 컎퍌니 항-cd73 항ìČŽì™€ì˜ ìĄ°í•© 요ëȕ
CN105732643A (zh) * 2016-04-18 2016-07-06 è‹ć·žć€§ć­Š äž€ç§ć¶è”ç‰©ă€ć…¶ćˆ¶ć€‡æ–čæł•ćŠćœšćˆ¶ć€‡idoé…¶æŠ‘ćˆ¶ć‰‚ć’Œéžç”Ÿäœ“æŠ—ç‚ŽèŻç‰©äž­çš„ćș”甚
US12297266B2 (en) 2016-04-18 2025-05-13 Celldex Therapeutics, Inc. Agonistic antibodies that bind human CD40 and uses thereof
CN107312005B (zh) * 2016-04-27 2021-12-17 äžŠæ”·çż°æŁźç”Ÿç‰©ćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž ć…·æœ‰ido/tdoæŠ‘ćˆ¶æŽ»æ€§çš„çš ćˆć’Șć”‘èĄç”Ÿç‰©ćŠć…¶ćˆ¶ć€‡æ–čæł•ć’Œćș”甚
JP2019516681A (ja) 2016-05-04 2019-06-20 ブăƒȘă‚čăƒˆăƒ«âˆ’ăƒžă‚€ăƒ€ăƒŒă‚ș ă‚čă‚Żă‚€ăƒ– ă‚«ăƒłăƒ‘ăƒ‹ăƒŒïŒąïœ’ïœ‰ïœ“ïœ”ïœïœŒâˆ’ïŒ­ïœ™ïœ…ïœ’ïœ“ ïŒłïœ‘ïœ•ïœ‰ïœ‚ïœ‚ ïŒŁïœïœïœïœïœŽïœ™ ă‚€ăƒłăƒ‰ăƒŒăƒ«ă‚ąăƒŸăƒłïŒ’ïŒŒïŒ“âˆ’ă‚žă‚Șă‚­ă‚·ă‚ČăƒŠăƒŒă‚Œé˜»ćźłć‰€ăŠă‚ˆăłăăźäœżç”šæ–čæł•
US10696648B2 (en) 2016-05-04 2020-06-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN109414420A (zh) 2016-05-04 2019-03-01 ç™Ÿæ—¶çŸŽæ–œèŽ”ćźć…Źćž ćČ據èƒș2,3-ćŒćŠ æ°§é…¶çš„æŠ‘ćˆ¶ć‰‚ćŠć…¶äœżç”šæ–čæł•
JP2019516682A (ja) 2016-05-04 2019-06-20 ブăƒȘă‚čăƒˆăƒ«âˆ’ăƒžă‚€ăƒ€ăƒŒă‚ș ă‚čă‚Żă‚€ăƒ– ă‚«ăƒłăƒ‘ăƒ‹ăƒŒïŒąïœ’ïœ‰ïœ“ïœ”ïœïœŒâˆ’ïŒ­ïœ™ïœ…ïœ’ïœ“ ïŒłïœ‘ïœ•ïœ‰ïœ‚ïœ‚ ïŒŁïœïœïœïœïœŽïœ™ ă‚€ăƒłăƒ‰ăƒŒăƒ«ă‚ąăƒŸăƒłïŒ’ïŒŒïŒ“âˆ’ă‚žă‚Șă‚­ă‚·ă‚ČăƒŠăƒŒă‚Œé˜»ćźłć‰€ăŠă‚ˆăłăăźäœżç”šæ–čæł•
US11066383B2 (en) 2016-05-04 2021-07-20 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP4491236A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109790143A (zh) 2016-05-10 2019-05-21 C4ćŒ»èŻć…Źćž 甹äșŽé¶è›‹ç™œé™è§Łçš„èƒșèżžæŽ„çš„c3-戊äșŒé…°äșšèƒșé™è§Łć†łćźšć­äœ“
CN109641874A (zh) 2016-05-10 2019-04-16 C4ćŒ»èŻć…Źćž 甹äșŽé¶è›‹ç™œé™è§Łçš„c3-çąłèżžæŽ„çš„æˆŠäșŒé…°äșšèƒșé™è§Łć†łćźšć­äœ“
CN105902542A (zh) * 2016-05-16 2016-08-31 ćŒ é˜ł äž€ç§ć¶è”ç‰©ćœšćˆ¶ć€‡æČ»ç–—ćżƒèĄ€çźĄç–Ÿç—…èŻç‰©äž­çš„ćș”甚
WO2017198159A1 (zh) * 2016-05-16 2017-11-23 éČć—ćˆ¶èŻé›†ć›ąè‚Ąä»œæœ‰é™ć…Źćž ć«æĄ„çŽŻçš„ć’Șć”‘èĄç”Ÿç‰©
CN107383012B (zh) * 2016-05-16 2021-09-28 éČć—ćˆ¶èŻé›†ć›ąè‚Ąä»œæœ‰é™ć…Źćž 搫äșŒçŽŻçš„ć’Șć”‘é†‡èĄç”Ÿç‰©
CN107556316B (zh) * 2016-06-30 2021-11-12 éČć—ćˆ¶èŻé›†ć›ąè‚Ąä»œæœ‰é™ć…Źćž ć«æĄ„çŽŻçš„ć’Șć”‘èĄç”Ÿç‰©
CN106957318B (zh) * 2016-05-19 2019-12-10 äž­ć›œç§‘ć­Šé™ąäžŠæ”·æœ‰æœșćŒ–ć­Šç ”ç©¶æ‰€ çš ćˆć€šçŽŻćČć“šć•‰ćŒ–ćˆç‰©ă€ć…¶ćˆ¶ć€‡æ–čæł•ă€èŻç‰©ç»„ćˆç‰©ćŠćș”甚
EP3439666A4 (en) 2016-05-20 2019-12-11 The University of Chicago NANOPARTICLES FOR CHEMOTHERAPY, TARGETED THERAPY, PHOTODYNAMIC THERAPY, IMMUNOTHERAPY AND ALL COMBINATIONS THEREOF
AR108586A1 (es) * 2016-06-10 2018-09-05 Lilly Co Eli Compuestos de 2,3-dihidro-1h-indol
CN107488179B (zh) * 2016-06-11 2024-06-07 éČć—ćˆ¶èŻé›†ć›ąè‚Ąä»œæœ‰é™ć…Źćž ć«æĄ„çŽŻçš„ć’Șć”‘é†‡èĄç”Ÿç‰©
CN107556315B (zh) * 2016-06-30 2021-08-31 éČć—ćˆ¶èŻé›†ć›ąè‚Ąä»œæœ‰é™ć…Źćž ć«ć››ć…ƒçŽŻçš„ć’Șć”‘èĄç”Ÿç‰©
MY200602A (en) 2016-07-14 2024-01-04 Bristol Myers Squibb Co Antibodies against tim3 and uses thereof
WO2018017633A1 (en) 2016-07-21 2018-01-25 Bristol-Myers Squibb Company TGF Beta RECEPTOR ANTAGONISTS
CN107663159A (zh) * 2016-07-29 2018-02-06 䞊攷èżȘèŻșćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž ć€šçŽŻćŒ–ćˆç‰©ă€ć…¶èŻç‰©ç»„ćˆç‰©ćŠćș”甚
WO2018028491A1 (zh) * 2016-08-09 2018-02-15 è‹ć·žć›œćŒĄćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž ćČ據èƒș23-ćŒćŠ æ°§é…¶æŠ‘ćˆ¶ć‰‚ćŠć…¶ćœšèŻć­Šäž­çš„ç”šé€”
WO2018039518A1 (en) 2016-08-26 2018-03-01 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN107383024B (zh) * 2016-09-12 2018-06-08 ćčżć·žćż…莝ç‰čćŒ»èŻæŠ€æœŻæœ‰é™ć…Źćž 搫ć’Șć”‘çš ćˆäž‰çŽŻç±»ćŒ–ćˆç‰©ćŠć…¶ćș”甚
TW201815766A (zh) 2016-09-22 2018-05-01 çŸŽć•†æ™źé›·èŸ›è‚Żć…Źćž ç”šæ–Œïœ‰ïœ„ïœćŠïœ”ïœ„ïœèȘżçŻ€äč‹ćŒ–ćˆç‰©ćŠæ–čæł•ä»„ćŠć…¶é©æ‡‰ç—‡
EP3515914A4 (en) 2016-09-24 2020-04-15 BeiGene, Ltd. INNOVATIVE 5- OR 8-SUBSTITUTED IMIDAZO [1,5-A] PYRIDINE AS SELECTIVE INHIBITORS OF INDOLEAMINE AND / OR TRYPTOPHANE-2,3-DIOXYGENASES
BR112019006652A2 (pt) 2016-10-13 2019-07-02 Juno Therapeutics Inc métodos e composiçÔes para imunoterapia envolvendo moduladores da via metabólica do triptofano
TW201815793A (zh) * 2016-10-21 2018-05-01 æ±Ÿè˜‡æ†ç‘žé†«è—„è‚Ąä»œæœ‰é™ć…Źćž 侀繼ć’Ș攑侩異ćČć“šéĄžèĄç”Ÿç‰©çš„éŠé›ąéčŒçš„ç”æ™¶ćœąćŒćŠć…¶èŁœć‚™æ–čæł•
WO2018072743A1 (zh) * 2016-10-21 2018-04-26 è‹ć·žç››èżȘäșšç”Ÿç‰©ćŒ»èŻæœ‰é™ć…Źćž Pd-1抗䜓䞎idoæŠ‘ćˆ¶ć‰‚è”ćˆćœšćˆ¶ć€‡æŠ—è‚żç˜€çš„èŻç‰©äž­çš„ç”šé€”
EP3535243B1 (en) 2016-11-04 2021-12-15 Auckland Uniservices Limited Substituted 9h-xanthen-9-one, 9h-thioxanthen-9-one and acridin-9(10h)-one derivatives and related compounds csf-1r inhibitors for the treatment of cancer
CN106474468B (zh) * 2016-11-23 2020-03-27 äž­ć›œćŒ»ć­Šç§‘ć­Šé™ąćŒ»ć­Šç”Ÿç‰©ć­Šç ”ç©¶æ‰€ äž€ç§ć€ćˆäœć‰‚ă€ć«èŻ„ć€ćˆäœć‰‚çš„ç–«è‹—ćŠç–«è‹—çš„ćˆ¶ć€‡æ–čæł•
WO2018106579A1 (en) * 2016-12-06 2018-06-14 Albert Einstein College Of Medicine, Inc. Drug targeting of human indoleamine 2,3-dioxygenase
CN108203438B (zh) * 2016-12-20 2021-09-28 æ·±ćœłćŸźèŠŻç”Ÿç‰©ç§‘æŠ€è‚Ąä»œæœ‰é™ć…Źćž ć…·æœ‰ćČ據èƒș2,3-ćŒćŠ æ°§é…¶æŠ‘ćˆ¶æŽ»æ€§çš„çš ćˆć’Șć”‘ćŒ–ćˆç‰©
SMT202100573T1 (it) 2016-12-22 2021-11-12 Calithera Biosciences Inc Composizioni e metodi per l'inibizione dell'attivita' dell'arginasi
CN108239091B (zh) * 2016-12-26 2021-08-13 äž­ć›œćŒ»ć­Šç§‘ć­Šé™ąèŻç‰©ç ”ç©¶æ‰€ 1-环深ćŸș-2-(5H-ć’Ș攑[5,1-a]ćŒ‚ćČ據)äč™ćŸș-1-é…źçš„æ‹†ćˆ†
US10961239B2 (en) 2017-01-05 2021-03-30 Bristol-Myers Squibb Company TGF beta receptor antagonists
JP2020506895A (ja) 2017-01-17 2020-03-05 ăƒœăƒŒăƒ‰ ă‚Șブ レゾェンツ, ă‚¶ ăƒŠăƒ‹ăƒăƒŒă‚·ăƒ†ă‚Ł ă‚Șブ ăƒ†ă‚­ă‚”ă‚č ă‚·ă‚čテムBoard Of Regents, The University Of Texas System ă‚€ăƒłăƒ‰ăƒŒăƒ«ă‚ąăƒŸăƒłïŒ’ïŒŒïŒ“âˆ’ă‚žă‚Șă‚­ă‚·ă‚ČăƒŠăƒŒă‚ŒăŠă‚ˆăłïŒăŸăŸăŻăƒˆăƒȘプトファンゾă‚Șă‚­ă‚·ă‚ČăƒŠăƒŒă‚Œăźé˜»ćźłć‰€ăšă—ăŠæœ‰ç”šăȘćŒ–ćˆç‰©
WO2018175954A1 (en) 2017-03-23 2018-09-27 F. Hoffmann-La Roche Ag Synthesis of imidazo[5,1-a]isoindole derivative useful as ido inhibitors
CA3057687A1 (en) 2017-03-31 2018-10-04 Five Prime Therapeutics, Inc. Combination therapy for cancer using anti-gitr antibodies
TWI788340B (zh) 2017-04-07 2023-01-01 çŸŽć•†ćż…æČ»ćŠ„çŸŽé›…ćČè°·æŻ”ć…Źćž 抗icosäżƒæ•ˆćŠ‘æŠ—é«”ćŠć…¶ç”šé€”
WO2018195397A2 (en) 2017-04-21 2018-10-25 Kyn Therapeutics Indole ahr inhibitors and uses thereof
WO2018201014A1 (en) 2017-04-28 2018-11-01 Five Prime Therapeutics, Inc. Methods of treatment with cd80 extracellular domain polypeptides
US11066392B2 (en) 2017-05-12 2021-07-20 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN107176956B (zh) * 2017-05-31 2019-11-12 æˆéƒœæ”·ćšé”èŻäžšæœ‰é™ć…Źćž 侀种idoæŠ‘ćˆ¶ć‰‚ćŒ–ćˆç‰©ă€èŻç”šç»„ćˆç‰©ă€ç”šé€”
EP4717317A2 (en) 2017-06-20 2026-04-01 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
JP7301757B2 (ja) 2017-06-26 2023-07-03 ăƒă‚€ă‚čă‚Żăƒ«ă‚ąăƒŒăƒ«ăƒ‡ă‚ŁăƒŒăƒ»ăƒȘミテッド 怜ć‡șćŻèƒœéƒšćˆ†ă‚’æŒă€äșŒç’°ćŒăƒšăƒ—ăƒăƒ‰ăƒȘă‚Źăƒłăƒ‰ăŠă‚ˆăłăăźäœżç”š
US11827639B2 (en) 2017-06-28 2023-11-28 Genentech, Inc. TDO2 and IDO1 inhibitors
EP3645533B1 (en) 2017-06-28 2025-03-26 Genentech, Inc. Tdo2 and ido1 inhibitors
US11236049B2 (en) 2017-06-30 2022-02-01 Bristol-Myers Squibb Company Amorphous and crystalline forms of IDO inhibitors
KR102709265B1 (ko) 2017-07-28 2024-09-23 ëžŒëŠŹìŠ€í†š-마읎얎슀 슀큅 컎퍌니 í•­ì•”ì œëĄœì„œì˜ 시큎늭 디뉎큎레였티드
EP3638367A4 (en) 2017-08-02 2021-07-21 The University of Chicago NANOMETRIC ORGANOMETALLIC AND NANOPLAQUE ORGANOMETALLIC LAYERS FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RADIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION OF THESE
CN111183147B (zh) 2017-08-04 2024-07-05 æ‹œæ–Żç§‘æŠ€æœŻćŒ€ć‘æœ‰é™ć…Źćž Cd137ç‰čćŒ‚æ€§çš„ćŒçŽŻè‚œé…äœ“
TW201910336A (zh) * 2017-08-08 2019-03-16 ć€§é™žć•†æ±Ÿè˜‡æ†ç‘žé†«è—„è‚Ąä»œæœ‰é™ć…Źćž 侀繼ć’Ș攑ćč¶ç•°ćČć“šéĄžèĄç”Ÿç‰©çš„èŁœć‚™æ–čæł•
CN109384791B (zh) * 2017-08-09 2020-09-11 æ±Ÿè‹æ’ç‘žćŒ»èŻè‚Ąä»œæœ‰é™ć…Źćž 侀种ć’Ș攑ćč¶ćŒ‚ćČć“šç±»èĄç”Ÿç‰©æžžçŠ»çą±çš„æ™¶ćž‹ćŠć…¶ćˆ¶ć€‡æ–čæł•
WO2019036657A1 (en) 2017-08-17 2019-02-21 Kyn Therapeutics AHR INHIBITORS AND USES THEREOF
CA3072989A1 (en) 2017-08-17 2019-02-21 Idorsia Pharmaceuticals Ltd Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
CN111263763B (zh) * 2017-08-18 2021-02-19 æ­Łć€§ć€©æ™ŽèŻäžšé›†ć›ąè‚Ąä»œæœ‰é™ć…Źćž 侀种侉ćč¶çŽŻćŒ–ćˆç‰©çš„ç»“æ™¶
JP6934562B2 (ja) * 2017-08-22 2021-09-15 ゼăƒȘă‚ąăƒŒăƒ‰ ă‚”ă‚€ă‚šăƒłă‚·ăƒŒă‚ș ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ æČ»ç™‚ç”šè€‡çŽ ç’°ćŒćŒ–ćˆç‰©
US10947263B2 (en) 2017-08-31 2021-03-16 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
ES2904317T3 (es) 2017-08-31 2022-04-04 Bristol Myers Squibb Co DinucleĂłtidos cĂ­clicos como agentes anticancerosos
US11667663B2 (en) 2017-08-31 2023-06-06 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
CN107501272B (zh) * 2017-09-05 2020-03-31 äž­ć›œèŻç§‘ć€§ć­Š ć’Ș攑ćč¶ćŒ‚ćČ據类ido1æŠ‘ćˆ¶ć‰‚ă€ć…¶ćˆ¶ć€‡æ–čæł•揩ćș”甚
WO2019055786A1 (en) 2017-09-14 2019-03-21 Lankenau Institute For Medical Research METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
WO2019060693A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES THEREOF
MX2020003190A (es) 2017-09-22 2020-11-11 Kymera Therapeutics Inc Degradadores de proteinas y usos de los mismos.
US11203592B2 (en) 2017-10-09 2021-12-21 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11649212B2 (en) 2017-10-09 2023-05-16 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11660311B2 (en) 2017-10-10 2023-05-30 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
EP3694552A1 (en) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
US11427610B2 (en) 2017-10-16 2022-08-30 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019078246A1 (ja) 2017-10-19 2019-04-25 äž€èˆŹç€Ÿć›Łæł•äșșăƒ•ă‚Ąăƒ«ăƒžăƒăƒŹăƒŒăƒ—ăƒ­ă‚žă‚§ă‚Żăƒˆæ”ŻæŽæ©Ÿæ§‹ ïŒ©ïœ„ïœïŒïœ”ïœ„ïœé˜»ćźłć‰€
CN111542544A (zh) 2017-11-01 2020-08-14 ç™Ÿæ—¶çŸŽæ–œèŽ”ćźć…Źćž 甹äșŽæČ»ç–—ç™Œç—‡çš„ć…ç–«ćˆșæż€æ€§æż€ćŠšæ€§æŠ—äœ“
JP7167146B2 (ja) 2017-11-06 2022-11-08 ブăƒȘă‚čăƒˆăƒ«ïŒăƒžă‚€ăƒ€ăƒŒă‚ș ă‚čă‚Żă‚€ăƒ– ă‚«ăƒłăƒ‘ăƒ‹ăƒŒ ïŒšïœïœ‹ïŒ‘é˜»ćźłć‰€ăšă—ăŠæœ‰ç”šăȘă‚€ă‚œăƒ•ăƒ©ăƒŽăƒłćŒ–ćˆç‰©
CN111386114A (zh) 2017-11-25 2020-07-07 ç™Ÿæ”Žç„žć·žæœ‰é™ć…Źćž 䜜äžșćČ據èƒș2,3-ćŒćŠ æ°§é…¶çš„é€‰æ‹©æ€§æŠ‘ćˆ¶ć‰‚çš„æ–°éą–è‹Żćč¶ć’Ș攑
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
CN111788227B (zh) 2017-12-27 2025-02-25 ç™Ÿæ—¶çŸŽæ–œèŽ”ćźć…Źćž 抗cd40æŠ—äœ“ćŠć…¶ç”šé€”
US11447449B2 (en) 2018-01-05 2022-09-20 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019140387A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
KR20250078626A (ko) 2018-01-12 2025-06-02 ëžŒëŠŹìŠ€í†š-마읎얎슀 슀큅 컎퍌니 Tim3에 대한 항ìČŽ 및 귞의 용도
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
EP3740493B1 (en) 2018-01-15 2021-12-01 Idorsia Pharmaceuticals Ltd Inhibteurs de l'indoleamine 2,3-dioxygénase et/ou du tryptophane dioxygénase
WO2019141095A1 (zh) * 2018-01-19 2019-07-25 ć››ć·ç§‘äŒŠćšæł°ç”Ÿç‰©ćŒ»èŻè‚Ąä»œæœ‰é™ć…Źćž è„’ç±»ć’Œèƒç±»èĄç”Ÿç‰©ă€ć…¶ćˆ¶ć€‡æ–čæł•ćŠć…¶ćœšćŒ»èŻäžŠçš„ćș”甚
EP3746071A4 (en) 2018-01-29 2021-09-01 Merck Patent GmbH GCN2 INHIBITORS AND THEIR USES
KR20200116481A (ko) 2018-01-29 2020-10-12 메넎큏 파텐튾 êČŒì— ëȠ하 Gcn2 얔제제 및 읎의 용도
US10519187B2 (en) 2018-02-13 2019-12-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
JP2021514953A (ja) 2018-02-23 2021-06-17 ăƒă‚€ă‚čă‚Żăƒ«ăƒ†ă‚Żă‚č・ăƒȘミテッド ć€šé‡äœ“äșŒç’°ćŒăƒšăƒ—ăƒăƒ‰ăƒȘガンド
KR20200130362A (ko) 2018-03-08 2020-11-18 ëžŒëŠŹìŠ€í†š-마읎얎슀 슀큅 컎퍌니 í•­ì•”ì œëĄœì„œì˜ 시큎늭 디뉎큎레였티드
AU2019239952A1 (en) 2018-03-20 2020-10-08 Plexxikon Inc. Compounds and methods for IDO and TDO modulation, and indications therefor
BR112020019083A2 (pt) 2018-03-21 2020-12-29 Five Prime Therapeutics, Inc. Anticorpos, åcido nucleico, composiçÔes, célula e métodos para preparar um anticorpo, para tratar cùncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficåcia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficåcia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar cùncer
PE20210665A1 (es) 2018-03-23 2021-03-31 Bristol Myers Squibb Co Anticuerpos contra mica y/o micb y sus usos
US20210147570A1 (en) 2018-04-12 2021-05-20 Bristol-Myers Squibb Company Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
US10973834B2 (en) 2018-04-16 2021-04-13 Arrys Therapeutics, Inc. EP4 inhibitors and use thereof
US12037323B2 (en) 2018-05-03 2024-07-16 Bristol-Myers Squibb Company Uracil derivatives as Mer-AXL inhibitors
IL279489B2 (en) 2018-06-22 2025-10-01 Bicycletx Ltd Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
PT3814347T (pt) 2018-06-27 2023-07-18 Bristol Myers Squibb Co Compostos de naftiridinona Ășteis como ativadores de cĂ©lulas t
CN112654621B (zh) 2018-06-27 2024-05-14 ç™Ÿæ—¶çŸŽæ–œèŽ”ćźć…Źćž ćŻäœœäžștç»†èƒžæŽ»ćŒ–ć‰‚çš„ç»ć–ä»Łè˜ć•¶é…źćŒ–ćˆç‰©
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
TW202428604A (zh) 2018-07-09 2024-07-16 çŸŽć•†æˆŠç‘žæČ»ç™‚æœ‰é™ć…Źćž ç”ćˆè‡łilt4的抗體
BR112021000303A2 (pt) 2018-07-11 2021-04-13 Five Prime Therapeutics, Inc. Anticorpos que se ligam a vista em ph ĂĄcido
WO2020018670A1 (en) 2018-07-17 2020-01-23 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
US12059420B2 (en) 2018-07-23 2024-08-13 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2020023356A1 (en) 2018-07-23 2020-01-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10959986B2 (en) 2018-08-29 2021-03-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11253525B2 (en) 2018-08-29 2022-02-22 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US12030875B2 (en) 2018-09-07 2024-07-09 PIC Therapeutics, Inc. EIF4E inhibitors and uses thereof
KR102833434B1 (ko) 2018-09-27 2025-07-15 쉔젠 ìč©ìŠ€íŹëа ë°”ìŽì˜€ì‚ŹìŽì–žìŠ€ 씚였., 엘티디. ìžëŒì•„ëŻŒ-2,3-디옄시êČŒë‚˜ì•„ì œ 얔제 활성을 갖는 퀮놀며 유도ìČŽ
EP3863722A2 (en) 2018-10-10 2021-08-18 Tilos Theapeutics, Inc. Anti-lap antibody variants and uses thereof
US11274150B2 (en) 2018-11-16 2022-03-15 Bristol-Myers Squibb Company Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodies
JP7623943B2 (ja) 2018-11-30 2025-01-29 ă‚«ă‚€ăƒĄăƒ© ă‚»ăƒ©ăƒ”ăƒ„ăƒŒăƒ†ă‚Łă‚Żă‚č ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ïŒ©ïœ’ïœïœ‹ćˆ†è§Łć‰€ăŠă‚ˆăłăă‚Œă‚‰ăźäœżç”š
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
EP3670659A1 (en) 2018-12-20 2020-06-24 Abivax Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
CN120698983A (zh) 2018-12-20 2025-09-26 C4ćŒ»èŻć…Źćž é¶ć‘è›‹ç™œé™è§Ł
US12551567B2 (en) 2018-12-21 2026-02-17 Bicyclerd Limited Bicyclic peptide ligands specific for PD-L1
JP2022514618A (ja) 2018-12-21 2022-02-14 ăƒă‚€ă‚čă‚Żăƒ«ăƒ†ă‚Żă‚č・ăƒȘミテッド ïŒ°ïœ„ïŒïœŒïŒ‘ă«ç‰č異的ăȘäșŒç’°ćŒăƒšăƒ—ăƒăƒ‰ăƒȘガンド
CN120131907A (zh) 2019-03-19 2025-06-13 ç“Šć°”ćžŒäŒŻäŒŠç§äșșè‚żç˜€ç ”ç©¶ćŸș金䌚 采甹Omomycć’Œç»“ćˆPD-1或CTLA-4的抗䜓æČ»ç–—ç™Œç—‡çš„è”ćˆç–—æł•
US20220184222A1 (en) 2019-04-02 2022-06-16 Bicycletx Limited Bicycle toxin conjugates and uses thereof
TWI875749B (zh) 2019-04-05 2025-03-11 çŸŽć•†ć‡±éș„æ‹‰é†«ç™‚ć…Źćž Staté™è§ŁćŠ‘ćŠć…¶ç”šé€”
WO2020231713A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
WO2020231766A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
WO2020243423A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
BR112021026517A2 (pt) 2019-06-28 2022-05-10 Kymera Therapeutics Inc Degradadores de irak e usos dos mesmos
JP2022540146A (ja) 2019-07-11 2022-09-14 ă‚€ăƒ‰ăƒŒă‚·ă‚ą ăƒ•ă‚ĄăƒŒăƒžă‚·ăƒ„ăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚ș ăƒȘミテッド ă‚€ăƒłăƒ‰ăƒŒăƒ«ă‚ąăƒŸăƒł ïŒ’ïŒŒïŒ“ïŒă‚žă‚Șă‚­ă‚·ă‚ČăƒŠăƒŒă‚ŒćŠăłïŒćˆăŻăƒˆăƒȘプトファン ïŒ’ïŒŒïŒ“ïŒă‚žă‚Șă‚­ă‚·ă‚ČăƒŠăƒŒă‚Œăźé˜»ćźłć‰€
WO2021011868A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Irak degraders and uses thereof
TWI860386B (zh) 2019-07-30 2024-11-01 è‹±ć•†æ‹œè„żćŻæł°ć…‹æ–Żæœ‰é™ć…Źćž 異èłȘé›™ç’°è‚œè€‡ćˆç‰©
US20220306630A1 (en) 2019-08-06 2022-09-29 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos Ăștiles como activadores de cĂ©lulas t
CN114945366B (zh) 2019-09-13 2025-01-07 æž—äŒŻćŁ«èšéĄżć…Źćž Hpk1æ‹źæŠ—ć‰‚ć’Œć…¶ç”šé€”
EP4031575A1 (en) 2019-09-19 2022-07-27 Bristol-Myers Squibb Company Antibodies binding to vista at acidic ph
AU2020387392B2 (en) 2019-11-19 2025-09-11 Bristol-Myers Squibb Company Compounds useful as inhibitors of Helios protein
PT4065582T (pt) 2019-11-26 2025-05-22 Ikena Oncology Inc Derivados polimórficos do carbazol e utilizaçÔes dos mesmos
WO2021108288A1 (en) 2019-11-26 2021-06-03 Bristol-Myers Squibb Company Salts/cocrystals of (r)-n-(4-chlorophenyl)-2-((1s,4s)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide
US12551564B2 (en) 2019-12-10 2026-02-17 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
CN111333653A (zh) * 2019-12-16 2020-06-26 ć±±äžœć€§ć­Š 侀种icdèŻ±ćŻŒć‰‚-idoæŠ‘ćˆ¶ć‰‚çŒ€ćˆç‰©ćŠćˆ¶ć€‡æ–čæł•䞎ćș”甚
WO2021127283A2 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2021127190A1 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
IL294273A (en) 2019-12-23 2022-08-01 Bristol Myers Squibb Co Substituted heteroaryl compounds are useful as t-cell activators
BR112022012410A2 (pt) 2019-12-23 2022-08-30 Kymera Therapeutics Inc Degradadores smarca e usos dos mesmos
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicĂ­clicos sustituidos Ăștiles como activadores de cĂ©lulas t
KR20220119456A (ko) 2019-12-23 2022-08-29 ëžŒëŠŹìŠ€í†š-마읎얎슀 슀큅 컎퍌니 T ì„žíŹ í™œì„±í™”ì œëĄœì„œ 유용한 ìč˜í™˜ëœ 퀮놀멬녾닐 플페띌진 í™”í•©ëŹŒ
EP4081522A1 (en) 2019-12-23 2022-11-02 Bristol-Myers Squibb Company Substituted piperazine derivatives useful as t cell activators
CN114846007B (zh) 2019-12-23 2024-11-22 ç™Ÿæ—¶çŸŽæ–œèŽ”ćźć…Źćž ćŻç”šäœœtç»†èƒžæż€æŽ»ć‰‚çš„ç»ć–ä»Łçš„ć–č攑敉ćŸșćŒ–ćˆç‰©
BR112022013424A2 (pt) 2020-01-06 2022-12-13 Hifibio Hk Ltd Anticorpo anti-tnfr2 e seus usos
KR20220123105A (ko) 2020-01-07 2022-09-05 하읎파읎바읎였 (에읎ìč˜ìŒ€ìŽ) 멬믾티드 항-갈렉틎-9 항ìČŽ 및 ê·žêČƒì˜ 용도
EP4090663A1 (en) 2020-01-15 2022-11-23 Blueprint Medicines Corporation Map4k1 inhibitors
AU2021230289A1 (en) 2020-03-03 2022-09-29 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
WO2021183428A1 (en) 2020-03-09 2021-09-16 Bristol-Myers Squibb Company Antibodies to cd40 with enhanced agonist activity
US12528785B2 (en) 2020-03-19 2026-01-20 Kymera Therapeutics, Inc. MDM2 degraders and uses thereof
TW202140441A (zh) 2020-03-23 2021-11-01 çŸŽć•†ćż…æČ»ćŠ„çŸŽé›…ćČè°·æŻ”ć…Źćž ç¶“ć–ä»Łäč‹ćŽæ°§ćŸș異ćČć“šć•‰ćŒ–ćˆç‰©
EP4132971A1 (en) 2020-04-09 2023-02-15 Merck Sharp & Dohme LLC Affinity matured anti-lap antibodies and uses thereof
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
TW202210483A (zh) 2020-06-03 2022-03-16 çŸŽć•†ć‡±éș„æ‹‰é†«ç™‚ć…Źćž Iraké™è§ŁćŠ‘äč‹ç”æ™¶ćž‹
WO2021247897A1 (en) 2020-06-03 2021-12-09 Kymera Therapeutics, Inc. Deuterated irak degraders and uses thereof
CN111803635B (zh) * 2020-06-17 2023-03-14 äž­ć›œćŒ»ć­Šç§‘ć­Šé™ąćŸșçĄ€ćŒ»ć­Šç ”ç©¶æ‰€ ć°ćˆ†ć­æŠ‘ćˆ¶ć‰‚ćœšæČ»ç–—ć‘Œćžé“ç—…æŻ’æ€§è‚ș炎侊的ćș”甚
WO2021258010A1 (en) 2020-06-19 2021-12-23 Gossamer Bio Services, Inc. Oxime compounds useful as t cell activators
US11839659B2 (en) 2020-07-02 2023-12-12 Northwestern University Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein
US11857535B2 (en) 2020-07-30 2024-01-02 Kymera Therapeutics, Inc. Methods of treating mutant lymphomas
IL300248A (en) 2020-08-03 2023-03-01 Bicycletx Ltd peptide-based linkers
CN116724051A (zh) 2020-08-10 2023-09-08 äžŠæ”·ćŻ»ç™ŸäŒšç”Ÿç‰©æŠ€æœŻæœ‰é™ć…Źćž 甹äșŽé€šèż‡é¶ć‘igsf8杄æČ»ç–—è‡Șèș«ć…ç–«æ€§ç–Ÿç—…ć’Œç™Œç—‡çš„ç»„ćˆç‰©ć’Œæ–čæł•
WO2022038158A1 (en) 2020-08-17 2022-02-24 Bicycletx Limited Bicycle conjugates specific for nectin-4 and uses thereof
CA3198456A1 (en) 2020-10-14 2022-04-21 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
EP4255895A1 (en) 2020-12-02 2023-10-11 Ikena Oncology, Inc. Tead inhibitors and uses thereof
EP4259144A4 (en) 2020-12-09 2025-08-20 Kymera Therapeutics Inc SMARCA DEGRADING AGENTS AND THEIR USES
EP4262986A1 (en) 2020-12-16 2023-10-25 Gossamer Bio Services, Inc. Compounds useful as t cell activators
PH12023500015A1 (en) 2020-12-30 2024-03-11 Kymera Therapeutics Inc Irak degraders and uses thereof
US20250186539A2 (en) 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
EP4288427A1 (en) 2021-02-02 2023-12-13 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
JP2024506858A (ja) 2021-02-02 2024-02-15 ăƒȘăƒŸăƒŠăƒ«ăƒ»ăƒă‚€ă‚Șă‚”ă‚€ă‚šăƒłă‚·ăƒŒă‚ș・ăƒȘミテッド ïŒ§ïœïœ’ïŒ˜ïŒ”ă‚ąăƒłă‚żă‚Žăƒ‹ă‚čăƒˆăŠă‚ˆăłăăźäœżç”š
WO2022169921A1 (en) 2021-02-04 2022-08-11 Bristol-Myers Squibb Company Benzofuran compounds as sting agonists
JP7821808B2 (ja) 2021-02-12 2026-02-27 ă‚šăƒ•ăƒ»ăƒ›ăƒ•ăƒžăƒłïŒăƒ©ăƒ»ăƒ­ă‚·ăƒ„ăƒ»ă‚ąă‚Żăƒă‚§ăƒłă‚Čă‚Œăƒ«ă‚·ăƒŁăƒ•ăƒˆ がんぼæČ»ç™‚ăźăŸă‚ăźäșŒç’°ćŒăƒ†ăƒˆăƒ©ăƒ’ăƒ‰ăƒ­ă‚ąă‚Œăƒ”ăƒłèȘ˜ć°Žäœ“
CN117120090A (zh) 2021-02-12 2023-11-24 æž—äŒŻćŁ«èšéĄżć…Źćž Hpk1æ‹źæŠ—ć‰‚ć’Œć…¶ç”šé€”
CN116867494A (zh) 2021-02-15 2023-10-10 懯éșŠæ‹‰ćŒ»ç–—ć…Źćž Irak4é™è§Łć‰‚ć’Œć…¶ç”šé€”
WO2022174268A1 (en) 2021-02-15 2022-08-18 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
WO2022184930A2 (en) 2021-03-05 2022-09-09 UniversitÀt Basel Compositions for the treatment of ebv associated diseases or conditions
EP4052705A1 (en) 2021-03-05 2022-09-07 UniversitÀt Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions
EP4301756A4 (en) 2021-03-05 2025-02-26 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
JP2024510176A (ja) 2021-03-08 2024-03-06 ăƒ–ăƒ«ăƒŒăƒ—ăƒȘント ăƒĄăƒ‡ă‚Łă‚·ăƒłă‚ș ă‚łăƒŒăƒăƒŹă‚€ă‚·ăƒ§ăƒł ïŒ­ïœïœïŒ”ïœ‹ïŒ‘é˜»ćźłć‰€
US11918582B2 (en) 2021-03-15 2024-03-05 Rapt Therapeutics, Inc. Pyrazole pyrimidine compounds and uses thereof
WO2022213062A1 (en) 2021-03-29 2022-10-06 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
JP2024514530A (ja) 2021-04-02 2024-04-02 ă‚¶ ăƒȘăƒŒă‚žă‚§ăƒłăƒ„ ă‚Șブ ă‚¶ ăƒŠăƒ‹ăƒăƒŒă‚·ăƒ†ă‚Ł ă‚Șブ ă‚«ăƒȘăƒ•ă‚©ăƒ«ăƒ‹ă‚ą ćˆ‡æ–­ćž‹ïœƒïœ„ïœƒïœïŒ‘ă«ćŻŸă™ă‚‹æŠ—äœ“ăŠă‚ˆăłăăźäœżç”š
BR112023020410A2 (pt) 2021-04-05 2023-11-28 Bristol Myers Squibb Co Compostos de oxoisoindolina substituĂ­da por piridinila para tratamento de cĂąncer
BR112023020077A2 (pt) 2021-04-06 2023-11-14 Bristol Myers Squibb Co Compostos de oxoisoindolina substituĂ­da por piridinila
AU2022256074A1 (en) 2021-04-09 2023-11-02 Nimbus Clio, Inc. Cbl-b modulators and uses thereof
JP2024514879A (ja) 2021-04-16 2024-04-03 ă‚€ă‚±ăƒŠ ă‚Șăƒłă‚łăƒ­ă‚žăƒŒïŒŒ ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ïŒ­ïœ…ïœ‹é˜»ćźłć‰€ćŠăłăăźäœżç”š
AU2022271290A1 (en) 2021-05-07 2023-11-23 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
KR20240083168A (ko) 2021-07-14 2024-06-11 뾔룹프며튾 메디신슈 ìœ”íŹë ˆìŽì…˜ Map4k1 ì €í•Žì œëĄœì„œì˜ í—€í…ŒëĄœì‚ŹìŽíŽ í™”í•©ëŹŒ
US20240336630A1 (en) 2021-07-15 2024-10-10 Blueprint Medicines Corporation Map4k1 inhibitors
US12157732B2 (en) 2021-08-25 2024-12-03 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
JP2024534127A (ja) 2021-08-25 2024-09-18 ピク ă‚»ăƒ©ăƒ”ăƒ„ăƒŒăƒ†ă‚Łă‚Żă‚č ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ïœ…ïŒ©ïŒŠïŒ”ïŒ„é˜»ćźłć‰€ćŠăłăăźäœżç”š
US12187744B2 (en) 2021-10-29 2025-01-07 Kymera Therapeutics, Inc. IRAK4 degraders and synthesis thereof
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2023122777A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
WO2023122772A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
WO2023122778A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Pyridazinone derivatives useful as t cell activators
EP4472967A4 (en) 2022-01-31 2026-04-15 Kymera Therapeutics Inc Iraqi Degradation Agents and Their Uses
EP4472963A1 (en) 2022-02-01 2024-12-11 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023211889A1 (en) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Polymorphic compounds and uses thereof
IL316768A (en) 2022-05-25 2025-01-01 Ikena Oncology Inc MEK inhibitors and their uses
JP2025527247A (ja) 2022-08-02 2025-08-20 ăƒȘăƒŸăƒŠăƒ«ăƒ»ăƒă‚€ă‚Șă‚”ă‚€ă‚šăƒłă‚·ăƒŒă‚ș・ăƒȘミテッド ケăƒȘăƒŒăƒ«ïŒăƒˆăƒȘă‚ąă‚ŸăƒȘăƒ«ćŠăłé–ąé€Łă™ă‚‹ïœ‡ïœïœ’ïŒ˜ïŒ”ă‚ąăƒłă‚żă‚Žăƒ‹ă‚čトăȘă‚‰ăłă«ăă‚Œă‚‰ăźäœżç”š
CN120051456A (zh) 2022-08-02 2025-05-27 é‡Œç±łèŻșç”Ÿç‰©ç§‘ć­Šæœ‰é™ć…Źćž ć–ä»Łçš„ćĄć•¶é…źgpr84æ‹źæŠ—ć‰‚ćŠć…¶ç”šé€”
IL318575A (en) 2022-08-02 2025-03-01 Liminal Biosciences Ltd HETEROARYL CARBOXAMIDE AND GPR84-RELATED ANTAGONISTS AND USES THEREOF
US20260049068A1 (en) 2022-08-08 2026-02-19 Bristol-Myers Squibb Company Substituted Tetrazolyl Compounds Useful as T Cell Activators
KR20250046310A (ko) 2022-08-09 2025-04-02 ëžŒëŠŹìŠ€í†š-마읎얎슀 슀큅 컎퍌니 T ì„žíŹ í™œì„±í™”ì œëĄœì„œ 유용한 3꞉ ì•„ëŻŒ ìč˜í™˜ëœ ëč„시큎늭 í™”í•©ëŹŒ
WO2024033388A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
CR20250043A (es) 2022-08-11 2025-03-25 Hoffmann La Roche Derivados bicĂ­clicos de tetrahidrotiazepina
WO2024033457A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
TW202417001A (zh) 2022-08-11 2024-05-01 ç‘žćŁ«ć•†è”«ć­šć­Ÿæ‹‰çŸ…è‚Ąä»œć…Źćž é›™ç’°ć››æ°«ć–ć‘ŻèĄç”Ÿç‰©
US20240208961A1 (en) 2022-11-22 2024-06-27 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
CN116143726B (zh) * 2022-12-02 2024-09-06 ćčżć·žćž‚è”ç‘žćˆ¶èŻæœ‰é™ć…Źćž äž€ç§çŽŻçŁ·è…șè‹·æ‚èŽšçš„ćˆ¶ć€‡æ–čæł•
WO2024137865A1 (en) 2022-12-22 2024-06-27 Gossamer Bio Services, Inc. Compounds useful as t cell activators
PE20260451A1 (es) 2023-05-08 2026-02-25 Bristol Myers Squibb Co Compuestos de feniloxazolona sustituida
EP4709712A1 (en) 2023-05-10 2026-03-18 Blueprint Medicines Corporation Gsk3a inhibitors and methods of use thereof
AU2024281056A1 (en) 2023-05-31 2026-01-22 Bristol-Myers Squibb Company Substituted oxazolone compound for decreasing levels of ikzf1-4 proteins
EP4724149A1 (en) 2023-06-07 2026-04-15 Bristol-Myers Squibb Company Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound
AU2024314878A1 (en) 2023-06-23 2026-01-22 Bristol-Myers Squibb Company Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent
IL321486A (en) 2023-06-23 2025-08-01 Kymera Therapeutics Inc Iraqi joints and their uses
WO2025030002A2 (en) 2023-08-02 2025-02-06 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
TW202525802A (zh) 2023-09-02 2025-07-01 çŸŽć•†ćż…æČ»ćŠ„çŸŽé›…ćČè°·æŻ”ć…Źćž ç¶“ć–ä»Łäč‹è‹ŻćŸșæ°§ä»Łă—ć”‘ćŸșć“Œć•¶äșŒé…źćŒ–ćˆç‰©
IL326828A (en) 2023-09-02 2026-04-01 Bristol Myers Squibb Co Piperidine-2,6-dione azatidinyl oxoisoindolinyl substituted compounds
FI4587429T3 (fi) 2023-09-13 2026-03-24 Bristol Myers Squibb Co Substituoituja oksoindolinyylipiperidiini-2,6-dioniyhdisteitÀ
WO2025096505A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096488A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096490A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096489A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096494A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096487A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
TW202535865A (zh) 2023-10-31 2025-09-16 çŸŽć•†ćż…æČ»ćŠ„çŸŽé›…ćČè°·æŻ”ć…Źćž æł›çŽ ç‰čç•°æ€§ćŠ ć·„è›‹ç™œé…¶1 (usp1) ćŒ–ćˆç‰©
WO2025226767A1 (en) 2024-04-24 2025-10-30 Bristol-Myers Squibb Company Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer
WO2026035787A1 (en) 2024-08-07 2026-02-12 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) macrocyles
WO2026080794A1 (en) 2024-10-11 2026-04-16 Bristol-Myers Squibb Company Chemical compounds useful for degrading proteins
CN119707950A (zh) * 2024-12-24 2025-03-28 æ— é”Ąćž‚ć—äșŹć€§ć­Šé”Ąć±±ćș”ç”šç”Ÿç‰©æŠ€æœŻç ”ç©¶æ‰€ 侀种甹äșŽć…ç–«è›‹ç™œé¶ć‘é™è§Łçš„ć”Œćˆäœ“ćŠć…¶ćˆ¶ć€‡æ–čæł•ć’Œćș”甚

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3476195D1 (en) 1983-05-18 1989-02-23 Ciba Geigy Ag Cyclohexanedione-carboxylic-acid derivatives having a herbicidal and plant growth regulating activity
US5807892A (en) 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
WO1999029310A2 (en) 1997-12-05 1999-06-17 Medical College Of Georgia Research Institute, Inc. Regulation of t cell-mediated immunity by tryptophan and its analogs
EP1501918A4 (en) 2002-04-12 2006-03-29 Med College Georgia Res Inst ANTIGEN PRESENTING CELL POPULATIONS AND THEIR USE AS REAGENTS TO INCREASE OR REDUCE IMMUNO TOLERANCE
WO2004094409A1 (en) 2003-03-27 2004-11-04 Lankenau Institute For Medical Research Novel ido inhibitors and methods of use
US7598287B2 (en) 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
JP2007520559A (ja) 2004-02-03 2007-07-26 ă‚ąăƒœăƒƒăƒˆăƒ»ăƒ©ăƒœăƒ©ăƒˆăƒȘăƒŒă‚ș æČ»ç™‚è–Źăšă—ăŠăźă‚ąăƒŸăƒŽăƒ™ăƒłă‚Ÿă‚Șă‚­ă‚”ă‚ŸăƒŒăƒ«éĄž
PL1879573T3 (pl) * 2005-05-10 2013-05-31 Incyte Holdings Corp Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
US7705022B2 (en) 2005-10-27 2010-04-27 Lankenau Institute For Medical Research IDO inhibitors and methods of use thereof
CA2634198C (en) 2005-12-20 2014-06-03 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
US8389568B2 (en) 2007-03-16 2013-03-05 Lankenau Institute For Medical Research IDO inhibitors and methods of use thereof
DE102007020493A1 (de) 2007-04-30 2008-11-06 GrĂŒnenthal GmbH Substituierte Amid-Derivate
JP5583592B2 (ja) 2007-11-30 2014-09-03 ăƒ‹ăƒ„ăƒŒăƒȘンク ゾェネティクă‚č ă‚łăƒŒăƒăƒŹă‚€ă‚·ăƒ§ăƒł ïŒ©ïœ„ïœé˜»ćźłć‰€
BRPI0821209A2 (pt) 2007-12-19 2019-09-24 Amgen Inc composto, composição farmacĂȘutica, mĂ©todos de tratar cĂąncer, para reduzir o tamanho de tumor, para tratar distĂșrbios, e para reduzir metĂĄstase em um tumor.
JP2011518841A (ja) * 2008-04-24 2011-06-30 ăƒ‹ăƒ„ăƒŒăƒȘンク ゾェネティクă‚č ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ïŒ©ïœ„ïœé˜»ćźłć‰€
PL2315756T3 (pl) 2008-07-08 2015-02-27 Incyte Holdings Corp 1,2,5-oksadiazole jako inhibitory 2,3-dioksygenazy indoloaminy
US8722720B2 (en) 2009-10-28 2014-05-13 Newlink Genetics Corporation Imidazole derivatives as IDO inhibitors
NO2694640T3 (me) * 2011-04-15 2018-03-17
JP2016501203A (ja) 2012-11-20 2016-01-18 ăƒăƒŒăƒ†ăƒƒă‚Żă‚č ăƒ•ă‚ĄăƒŒăƒžă‚·ăƒ„ăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚ș ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ïŒ¶ïœ…ïœ’ïœ”ïœ…ïœ˜   ă‚€ăƒłăƒ‰ăƒŒăƒ«ă‚ąăƒŸăƒłïŒ’ïŒŒïŒ“âˆ’ă‚žă‚Șă‚­ă‚·ă‚ČăƒŠăƒŒă‚Œăźé˜»ćźłć‰€ăšă—ăŠæœ‰ç”šăȘćŒ–ćˆç‰©
CN105209449B (zh) 2013-03-14 2019-02-01 ćș“æ‹‰ćŸ·ć€«ćˆ¶èŻç§äșșæœ‰é™ć…Źćž çŠŹć°żæ°šé…žé€”ćŸ„çš„æŠ‘ćˆ¶ć‰‚
WO2014141110A2 (en) 2013-03-14 2014-09-18 Curadev Pharma Pvt. Ltd. Aminonitriles as kynurenine pathway inhibitors
SG11201507255QA (en) 2013-03-14 2015-10-29 Newlink Genetics Corp Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
RS57462B1 (sr) 2013-03-15 2018-09-28 Bristol Myers Squibb Co Inhibitori indolamin 2,3-dioksigenaze (ido)
SG11201506920QA (en) 2013-03-15 2015-09-29 Bristol Myers Squibb Co Ido inhibitors
EA029126B1 (ru) 2013-07-01 2018-02-28 Đ‘Ń€ĐžŃŃ‚ĐŸĐ»-МаĐčДрс ĐĄĐșĐČОбб ĐšĐŸĐŒĐżĐ°ĐœĐž Đ˜ĐœĐłĐžĐ±ĐžŃ‚ĐŸŃ€Ń‹ ido
ES2707961T3 (es) 2013-07-11 2019-04-08 Bristol Myers Squibb Co Inhibidores de IDO

Also Published As

Publication number Publication date
HK1193822A1 (zh) 2014-10-03
PL3018132T3 (pl) 2018-05-30
DK2697227T3 (en) 2016-04-25
CA2833296C (en) 2020-12-08
US9260434B2 (en) 2016-02-16
CY1117440T1 (el) 2017-04-26
AU2012242871C1 (en) 2017-02-02
KR102164443B1 (ko) 2020-10-12
WO2012142237A8 (en) 2012-11-22
AU2016277574A1 (en) 2017-01-12
US9850248B2 (en) 2017-12-26
JP2014511876A (ja) 2014-05-19
AU2012242871B2 (en) 2014-09-11
AU2012242871A1 (en) 2013-10-31
PT3018132T (pt) 2018-03-09
PL2697227T3 (pl) 2016-09-30
SMT201600130B (it) 2016-07-01
US9388191B2 (en) 2016-07-12
RU2017107026A3 (me) 2019-01-23
PE20181023A1 (es) 2018-06-27
IL246515B (en) 2018-08-30
WO2012142237A1 (en) 2012-10-18
US20190225618A1 (en) 2019-07-25
ES2569665T3 (es) 2016-05-12
HUE027316T2 (en) 2016-10-28
AU2018202706A1 (en) 2018-05-10
RU2013150811A (ru) 2015-05-20
EP2697227A1 (en) 2014-02-19
AU2016277574B2 (en) 2018-04-19
AU2012242871A8 (en) 2013-11-21
NZ616457A (en) 2015-05-29
CN103547579B (zh) 2017-02-15
HUE038586T2 (hu) 2018-10-29
SI3018132T1 (en) 2018-04-30
CA2833296A1 (en) 2012-10-18
AU2014274564B2 (en) 2016-10-06
NO2694640T3 (me) 2018-03-17
RU2017107026A (ru) 2019-01-23
EP3018132A1 (en) 2016-05-11
HK1256355A1 (en) 2019-09-20
EP3348558A1 (en) 2018-07-18
KR20140059167A (ko) 2014-05-15
RS56992B1 (sr) 2018-05-31
JP2017149769A (ja) 2017-08-31
ES2660831T3 (es) 2018-03-26
IL228862A (en) 2015-10-29
US20180118753A1 (en) 2018-05-03
RS54723B1 (sr) 2016-08-31
JP2015061877A (ja) 2015-04-02
MX340442B (es) 2016-07-08
RU2613579C2 (ru) 2017-03-17
AU2014274564A1 (en) 2015-01-22
HK1223371A1 (en) 2017-07-28
DK3018132T3 (en) 2018-03-12
HRP20180335T1 (hr) 2018-04-20
CO6862146A2 (es) 2014-02-10
IL228862A0 (en) 2013-12-31
NZ723271A (en) 2018-03-23
IL241846A0 (en) 2015-11-30
JP2016029092A (ja) 2016-03-03
NZ708090A (en) 2016-12-23
US20160002249A1 (en) 2016-01-07
US10233190B2 (en) 2019-03-19
PE20141124A1 (es) 2014-09-06
HRP20160369T1 (hr) 2016-06-03
JP6145491B2 (ja) 2017-06-14
EP2697227B1 (en) 2016-02-03
CN105111210B (zh) 2018-10-09
SI2697227T1 (sl) 2016-06-30
BR112013026494A2 (pt) 2016-12-27
US20160362412A1 (en) 2016-12-15
EP3018132B1 (en) 2017-12-13
US20140066625A1 (en) 2014-03-06
MX2013012021A (es) 2014-07-10
CN105111210A (zh) 2015-12-02
CL2013002990A1 (es) 2014-07-04
LT3018132T (lt) 2018-03-26
IL241846A (en) 2016-06-30
JP5837673B2 (ja) 2015-12-24
CN103547579A (zh) 2014-01-29

Similar Documents

Publication Publication Date Title
IL246515B (en) Imidazole derivatives are designed for use as ido inhibitors
ZA201303801B (en) Fused aminodihydrothiazine derivatives useful as bace inhibitors
ZA201305612B (en) Pyrrolotriazinone derivatives as pi3k inhibitors
SG10201601802YA (en) Dispiropyrrolidine derivatives
IL233366A0 (en) Tetra or penta pyridophthalazinones are conjugated as parp inhibitors
IL227252A0 (en) Aminodihydrothiazine history from sisterhood
ZA201305826B (en) Substituted amminobutyric derivatives as neprilysin inhibitors
IL233365A0 (en) Tetra or pentacyclic dihydrodiazepinocarbazolones are conjugated as parp inhibitors
IL228949A0 (en) History of pyrazolospiroctone for use as acetyl-CoA carboxylase inhibitors
AP3529A (en) Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
IL258704B (en) History of hydantoins used as kv3 inhibitors
IL247636A0 (en) History of heteroaryl piperidine
IL229990A0 (en) History of n-oxypyrazolo-triazapine-dione
EP2744788A4 (en) BENZOPIPERAZINE DERIVATIVES AS CETP INHIBITORS
EP2703403A4 (en) imidazole
SI2766342T1 (sl) Derivati fenil-gvanidina
ZA201308049B (en) 3-ureidoisoquinolin-8-yl derivatives
PT2721009E (pt) Derivados de pirazole Ășteis como inibidores de aldosterona sintase
HK1186463A (en) Fused aminodihydrothiazine derivatives useful as bace inhibitors
ZA201209319B (en) Cyclopropyl-indole derivatives
ZA201308697B (en) Hydroxymethylaryl-substituted pyprolotriazines as alk1 inhibitors
GB201120474D0 (en) Inhibitors
GB201100183D0 (en) Fused aminodihydropyrimidone derivatives